Lisa Henderson

As a new industry survey shows, factoring in a generational cohort surfaces some provocative results related to key health indicators in clinical outsourcing relationships.

A view of highlights and trends from the September 2019 issue, alongside trends mentioned around site practices during the year.

A look at the opportunities and challenges around patient-centric trials and patient centricity in pharma.

A look at the latest oncology stats and information most applicable to the clinical trials industry practice.

Where pharmaceutical interventions for Alzheimer's falls short, nursing care facilities are relying heavily on non-traditional medicines and physical and mental exercise.

CROs should be more mindful of their smaller emerging biopharma clients and pay more attention to handling their needs.

Patient advocacy groups, patient centricity initiatives, and patient education are the key to putting patients at the center of clinical research.

A review of survey results looking at bridging clinical research and clinical health care.

From average merit increases from individual countries, to incentives per position, to retention bonuses and much more, a recent BDO report offers a robust look at an industry that has quickly eclipsed its “small company mentality” roots.

DIA Europe proves to have excellent timing to learn more about the latest developments in drug development, the current status of Brexit, the plans of the National regulators and EMA, on-going discussions on pan-European HTA, and the trends for 2019.

Supporting real change in clinical trials is more than just lip service-it’s putting the information out there transparently for all stakeholders to measure and make decisions.

Survey highlights thoughts on digital integration, managing data sources.

Blockchain is moving toward definitive uses in clinical trials to enhance clinical supply capabilities, with the potential of enabling data ownership for patients.

A multitude of data sources leaves clinical data management systems in catch-up mode-and researcher dizzy trying to follow the data- but there is hope for simplification on the horizon.

A look at current strategies from the industry that address the limitations in clinical trials.

Insights on the challenges, activity, and motives in merging bridging research and clinical care.

Although Biogen's Alzheimer's drug BAN2401 addresses buildup of amyloid plaques, investors and scientists look to reevaluate the plaque theory and search for a glimmer of hope in breakthrough treatments.

Editor-in-Chief Lisa Henderson speak about therapeutic needs, rare diseases in children, and the SCORR Marketing survey on innovative or flexible trial designs.

Findings from a new ACT and SCORR Marketing survey reveal the most actively used flexible design approaches in clinical research-many with application in rare disease.

May includes a number of events to get more visibility for clinical trial awareness, and to offer it as a care option.

Lisa Henderson talks about the topic of "who owns a patient's data" as discussed at the Bridging Clinical and Healthcare Conference 2018.

Lisa Henderson discusses randomized clinical trials with active and non-active placebo treatments.

Lisa Henderson writes on patient participation and recruitment in clinical trials.

Exploring the latest hiring and retention practices in the life sciences, where roles are changing fast. Impact trends from new talent survey are revealed.

Findings from a new ACT and SCORR Marketing survey reveal a gap in the shift to true patient-engagement in clinical trials, but overall measures do signal growth in patient-centric activities.

Lisa Henderson reports on the J.P. Morgan Healthcare conference and the balance of investment and science.

Dealmaking spurt and key upcoming regulatory guidances point the trajectory ahead in clinical research space.

Weighing overall workplace trends in the life sciences with new survey findings and views on job satisfaction.

The key to moving legacy systems-electronic or paper-to the cloud: Do it in doses-and learn from those who went before.